Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**mu-saporin** is a targeted immunotoxin composed of the ribosome-inactivating protein saporin chemically conjugated to a targeting molecule (typically an antibody, peptide, or ligand) specific for the mu (μ) opioid receptor. Saporin is derived from *Saponaria officinalis* and exerts its effect by depurinating adenine residues in the major rRNA, irreversibly inactivating ribosomes and thus blocking protein synthesis, leading to cell death[7][1][4]. As an immunotoxin, mu-saporin is commonly used in preclinical research to selectively ablate mu opioid receptor-expressing neurons for studies in pain, addiction, and neural circuit mapping. It does not inherently cross cell membranes and requires cell surface receptor-mediated internalization for toxicity[7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mu-saporin.